Biogen Defends Patent In Response To Petition For Inter Partes Review
Mealey's (November 14, 2018, 1:07 PM EST) -- ALEXANDRIA, Va. — Contrary to assertions by a petitioner for inter partes review (IPR), a patented regimen for treatment of low-grade, non-Hodgkin’s lymphoma is not obvious, patent owner Biogen Inc. maintains...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login